Highly sensitive target-based whole-cell antibacterial discovery strategy by antisense RNA silencing

Current Opinion in Drug Discovery and Development

Volumn 10, Issue 2, 2007, Pages 160-166

  Singh, Sheo B ^a   Phillips, John W ^a   Wang, Jun ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Antibiotic discovery; Antisense; Differential sensitization; Natural product; Screening

Indexed keywords

AMIKACIN; ANHYDROTETRACYCLINE; ANTIBIOTIC AGENT; AZITHROMYCIN; BOTTROMYCIN; CERULENIN; CIPROFLOXACIN; COMPLEMENTARY RNA; DACTINOMYCIN; ECHINOMYCIN; ERYTHROMYCIN; FOSFOMYCIN; FUSIDIC ACID; GENTAMICIN; KANAMYCIN; KASUGAMYCIN; MITOMYCIN C; MOCIMYCIN; NALIDIXIC ACID; NOVOBIOCIN; PLATENSIMYCIN; PUROMYCIN; RIFAMPICIN; SPECTINOMYCIN; TETRACYCLINE; THIOLACTOMYCIN; THIOTETROMYCIN; TRICLOSAN; TU 3010; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIBACTERIAL ACTIVITY; BACTERIAL GROWTH; BACTERIAL INFECTION; BACTERIAL STRAIN; CELL GROWTH; CELL STRUCTURE; DRUG EFFICACY; ENZYME INHIBITION; FATTY ACID SYNTHESIS; GENE EXPRESSION; GENETIC ENGINEERING; MOLECULAR CLONING; MONITORING; NONHUMAN; PHENOTYPE; REVIEW; SENSITIVITY ANALYSIS; STAPHYLOCOCCUS AUREUS; WHOLE CELL;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIA; DRUG DESIGN; GENE SILENCING; HUMANS; RNA; RNA, ANTISENSE;

EID: 33947313918     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (24)

1. Walsh CT (Ed): Antibiotics: Actions, Origin, Resistance. ASM Press, Washington DC, USA (2003). • An excellent book on antibiotics.
2. Singh SB, Barrett JF: Empirical antibacterial drug discoveryfoundation in natural products. Biochem Pharmacol (2006) 71(7):1006- 1015.
3. CDC Surveillance Systems and Published Data: Centers for Disease Control and Prevention, Atlanta, GA, USA (2004). http://www.cdc.gov/ drugresistance/technical/surveillance.htm#nnis
4. Young K, Silver LL: Leakage of periplasmic enzymes from envA1 strains of Escherichia coli. J Bacteriol (1991) 173(12):3609- 3614.
5. Poole K: Multidrug resistance in Gram-negative bacteria. Curr Opin Microbiol (2001) 4(5):500-508.
6. Markham PN, Neyfakh AA: Efflux-mediated drug resistance in Grampositive bacteria. Curr Opin Microbiol (2001) 4(5):509-514.
7. Forsyth RA, Haselbeck RJ, Ohlsen KL, Yamamoto RT, Xu H, Trawick JD, Wall D, Wang L, Brown-Driver V, Froelich JM, C KG et al: A genome-wide strategy for the identification of essential genes in Staphylococcus aureus. Mol Microbiol (2002) 43(6):1387-1400. •• One of the original papers describing xylose-induced expression of antisense RNA and the suggestion of its application in antibiotic discovery.
8. Ji Y, Yin D, Fox B, Holmes DJ, Payne D, Rosenberg M: Validation of antibacterial mechanism of action using regulated antisense RNA expression in Staphylococcus aureus. FEMS Microbiol Lett (2004) 231(2):177-184.
9. Berdy J: Bioactive microbial metabolites. J Antibiot (Tokyo) (2005) 58(1):1-26.
10. Akerley BJ, Rubin EJ, Novick VL, Amaya K, Judson N, Mekalanos JJ: A genome-scale analysis for identification of genes required for growth or survival of Haemophilus influenzae. Proc Natl Acad Sci USA (2002) 99(2):966-971.
11. Hutchison CA, Peterson SN, Gill SR, Cline RT, White O, Fraser CM, Smith HO, Venter JC: Global transposon mutagenesis and a minimal mycoplasma genome. Science (1999) 286(5447):2165-2169.
12. Ji Y, Zhang B, Van SF, Horn, Warren P, Woodnutt G, Burnham MK, Rosenberg M: Identification of critical staphylococcal genes using conditional phenotypes generated by antisense RNA. Science (2001) 293(5538):2266-2269. •• One of the original papers describing tet-induced expression of antisense RNA, demonstrating its application in the identification of essential genes.
13. Kobayashi K, Ehrlich SD, Albertini A, Amati G, Andersen KK, Arnaud M, Asai K, Ashikaga S, Aymerich S, Bessieres P, Boland F et al: Essential Bacillus subtilis genes. Proc Natl Acad Sci USA (2003) 100(8):4678-4683.
14. Young K, Jayasuriya H, Ondeyka JG, Herath K, Zhang C, Kodali S, Galgoci A, Painter R, Brown-Driver V, Yamamoto R, Silver LL et al: Discovery of FabH/FabF inhibitors from natural products. Antimicrob Agents Chemother (2006) 50(2):519-526. •• One of the original papers describing the application of antisense-based screening strategy for the discovery of antibiotics from natural products.
15. Wang J, Soisson SM, Young K, Shoop W, Kodali S, Galgoci A, Painter R, Parthasarathy G, Tang YS, Cummings R, Ha S, Dorso K et al: Platensimycin is a selective FabF inhibitor with potent antibiotic properties. Nature (2006) 441(7091):358-361. •• An excellent paper describing the discovery of a novel class of antibiotics using antisense strategy, elucidation of mechanism of action, structural biology and in vivo efficacy.
16. Singh SB, Jayasuriya H, Ondeyka JG, Herath KB, Zhang C, Zink DL, Tsou NN, Ball RG, Basilio A, Genilloud O, Diez MT et al: Isolation, structure, and absolute stereochemistry of platensimycin, a broad spectrum antibiotic discovered using an antisense differential sensitivity strategy. J Am Chem Soc (2006) 128(36):11916-11920.
17. Ondeyka JG, Zink DL, Young K, Painter R, Kodali S, Galgoci A, Collado J, Tormo JR, Basilio A, Vicente F, Wang J et al: Discovery of bacterial fatty acid synthase inhibitors from a Phoma species as antimicrobial agents using a new antisense-based strategy. J Nat Prod (2006) 69(3):377-380.
18. Ji Y, Marra A, Rosenberg M, Woodnutt G: Regulated antisense RNA eliminates α-toxin virulence in Staphylococcus aureus infection. J Bacteriol (1999) 181(21):6585-6590.
19. DeVito JA, Mills JA, Liu VG, Agarwal A, Sizemore CF, Yao Z, Stoughton DM, Cappiello MG, Barbosa MD, Foster LA, Pompliano DL: An array of target-specific screening strains for antibacterial discovery. Nat Biotechnol (2002) 20(5):478-483.
20. Matsumae A, Nomura S, Hata T: Studies on cerulenin. IV. Biological characteristics of cerulenin. J Antibiot (Tokyo) (1964) 17:1-7.
21. Heath RJ, Yu YT, Shapiro MA, Olson E, Rock CO: Broad spectrum antimicrobial biocides target the FabI component of fatty acid synthesis. J Biol Chem (1998) 273(46):30316-30320.
22. Miyakawa S, Suzuki K, Noto T, Harada Y, Okazaki H: Thiolactomycin, a new antibiotic. IV. Biological properties and chemotherapeutic activity in mice. J Antibiot (Tokyo) (1982) 35(4):411-419.
23. Rapp C, Jung G, Isselhorst-Schart C, Zahner H: A new member of the class of antibiotics with thiotetromic acid structure isolated from Streptomyces olivaceus Tü3010. Liebigs Ann Chem (1988):1043-1047.
24. Kodali S, Galgoci A, Young K, Painter R, Silver LL, Herath KB, Singh SB, Cully D, Barrett JF, Schmatz D, Wang J: Determination of selectivity and efficacy of fatty acid synthesis inhibitors. J Biol Chem (2005) 280(2):1669-1677.